—

Tubize-Fin (TUB.BR) — the peer cohort

As of 2026-10-06 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Tubize-Fin ranks 7 of 7 in its cohort on the Closelooknet composite (25/100) — the cohort is led by BB Biotech AG at 73/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
TUB.BR Tubize-Fin 25 11 20 27 warn 32%
BION.SW BB Biotech AG 73 59 96 81 info 12.9%
ONC BeiGene, Ltd. 64 78 66 32 ok 5.8%
REGN Regeneron Pharmaceuticals Inc 60 56 72 51 watch 15.5%
CAI Caris Life Sciences, Inc. Common Stock 59 80 63 26 ok 18.4%
PTGX Protagonist Therapeutics Inc 59 71 62 11 info 13.8%
TGTX TG Therapeutics Inc 54 69 68 28 info 12%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-06

Quick answers

Who are Tubize-Fin's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: BB Biotech AG (BION.SW), BeiGene, Ltd. (ONC), Regeneron Pharmaceuticals Inc (REGN), Caris Life Sciences, Inc. Common Stock (CAI), Protagonist Therapeutics Inc (PTGX), TG Therapeutics Inc (TGTX).

How does TUB.BR score against its peers?

Tubize-Fin's composite reads 25/100, ranking 7 of 7 in its cohort as of 2026-10-06; the cohort's highest composite is BB Biotech AG at 73/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.